Diaceutics (LON:DXRX) Reaches New 52-Week Low – Here’s What Happened

Diaceutics PLC (LON:DXRX) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 125 and last traded at GBX 127, with a volume of 224054 shares traded. The stock had previously closed at GBX 128.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group lifted their price objective on shares of Diaceutics from GBX 215 to GBX 216 and gave the company a “buy” rating in a report on Thursday, June 4th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of GBX 215.50.

Diaceutics Stock Performance

The firm has a market capitalization of £107.48 million, a price-to-earnings ratio of 1,154.55 and a beta of 0.89. The firm has a 50 day moving average price of GBX 143.48 and a 200-day moving average price of GBX 153.46. The company has a debt-to-equity ratio of 2.85, a current ratio of 3.43 and a quick ratio of 9.92.

Diaceutics (LON:DXRX) last released its earnings results on Tuesday, May 26th. The company reported GBX 11 EPS for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%.The firm had revenue of GBX 3,844 million during the quarter. As a group, sell-side analysts expect that Diaceutics PLC will post 1.0107919 earnings per share for the current fiscal year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.